Gemfibrozil 600mg tablets

BACKGROUND: Gemfibrozil (Gem) is a drug that has been shown to activate PPAR-α, a nuclear receptor that plays a key role in regulating lipid metabolism. Gem is used to lower the levels of triglycerides and reduce the risk of coronary heart disease in patients. Experimental studies in vitro and in vivo have shown that Gem can prevent or slow the progression of neurological disorders (NDs), including cerebral ischemia (CI), Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS). Neuroinflammation is known to play a significant role in these disorders. METHOD: The literature review for this study was conducted by searching Scopus, Science Direct, PubMed, and Google Scholar databases. RESULT: The results of this study show that Gem has neuroprotective effects through several cellular and molecular mechanisms such as: (1) Gem has the ability to upregulate pro-survival factors (PGC-1α and TFAM), promoting the survival and function of mitochondria in the brain, (2) Gem strongly inhibits the activation of NF-κB, AP-1, and C/EBPβ in cytokine-stimulated astroglial cells, which are known to increase the expression of iNOS and the production of NO in response to proinflammatory cytokines, (3) Gem protects dopamine neurons in the MPTP mouse model of PD by increasing the expression of PPARα, which in turn stimulates the production of GDNF in astrocytes, (4) Gem reduces amyloid plaque pathology, reduces the activity of glial cells, and improves memory, (5) Gem increases myelin genes expression (MBP and CNPase) via PPAR-β, and (6) Gem increases hippocampal BDNF to counteract depression. CONCLUSION: According to the study, Gem was investigated for its potential therapeutic effect in NDs. Further research is needed to fully understand the therapeutic potential of Gem in NDs.

Abstract licence: CC BY

The most documented fibrates are gemfibrozil, clofibrate and bezafibrate, while for statins, the majority of the published literature focuses on atorvastatin and simvastatin. The present work reviews previously published research concerning the effects of these hypocholesterolaemic pharmaceuticals on fish, with a particular focus on commercially important species, commonly produced by the European aquaculture industry, specifically in recirculated aquaculture systems (RAS). Overall, results suggest that both acute and chronic exposures to lipid-lowering compounds may have adverse effects on fish, disrupting their capacity to excrete exogenous substances, as well as both lipid metabolism and homeostasis, causing severe ontogenetic and endocrinological abnormalities, leading to hampered reproductive success (e.g., gametogenesis, fecundity), and skeletal or muscular malformations, having serious repercussions on fish health and welfare. Nonetheless, the available literature focusing on the effects of statins or fibrates on commonly farmed fish is still limited, and further research is required to understand the implications of this matter on aquaculture production, global food security and, ultimately, human health.

Abstract licence: CC BY

Abstract The contamination of ecosystems by pharmaceuticals and personal care products represents a significant threat to public health, necessitating innovative approaches to clean wastewater before release into aquatic environments. Here, we review the emerging strategies and methods for the remediation of gemfibrozil and carbamazepine, emphasizing toxicological impacts, advanced oxidation processes, membrane-based removal techniques, and the underlying mechanisms driving these removal processes. We found that engineered composites with strong electron transfer capabilities can enhance the removal efficiency as they boost the generation of highly oxidative radicals. For instance, a nano zero-valent ion incorporated carbon–nitrogen composite removes 100% of gemfibrozil within 60 min. Similarly, a ruthenium perovskite-based heterogeneous catalyst achieved 100% elimination of carbamazepine in 7.5 min.

Abstract licence: CC BY

Aim. To conduct a generalization of scientific research on the history of the use of medications for the correction of dyslipidemia in clinical practice. Materials and methods. The analysis and generalization of scientific articles, guidelines and recommendations on the justification and implementation of the appointment of hypolipidemic drugs for the treatment and prevention of cardiovascular diseases (CVD) was carried out. The methods used were: systematic approach, bibliosemantic, analytical. Results. Hypotheses regarding the role of hypercholesterolemia in the development of atherosclerotic lesions of the cardiovascular system were proposed as early as the second half of the 19th century, and scientific approaches regarding the need to correct dyslipidemia were substantiated only with the introduction of the concept of risk factors in the second half of the 20th century. However, it took almost two decades for the introduction of hypolipidemic drugs for the prevention and treatment of CVD into clinical practice. The first pharmacological drug that began to be used in clinical practice was nicotinic acid (niacin). Bile acid sequestrants (cholestyramine, colestipol, colesevelam) became the second group, and fibrates (fenofibrate, bezafibrate, gemfibrozil, and ciprofibrate) became the third group of hypolipidemic therapy drugs. Later, these drugs gave way to statins, whose clinical effectiveness was higher and the safety profile was better. Statin therapy is generally well tolerated and adverse reactions occur in less than 5% of randomized clinical trials. At the current stage, statins remain first-line drugs for the correction of lipid metabolism. The evidence base for statins is significant, and the results of randomized clinical trials have demonstrated the effectiveness of this group of drugs in the secondary and primary prevention of CVD. Since the end of the 90s of the 20th century, there has been a steady increase in the prescription of statins in clinical practice. Сonclusions. Medications for the correction of dyslipidemia have been used in clinical practice since the second half of the 20th century. Niacin, fibrates, and bile acid sequestrants have now been replaced by statins, which remain the first-line drugs for the correction of lipid metabolism.

Abstract licence: CC BY-NC

The lipid-regulating drug gemfibrozil is a useful medication for reducing high cholesterol and triglycerides in the blood. In addition to oxidation, it undergoes extensive glucuronidation to produce gemfibrozil acyl glucuronide, which is a known mechanism-based inactivator of cytochrome P450 (CYP) 2C8. Such selective and time-dependent inhibition results in clinically important drug-drug interactions (DDI) with the drugs metabolized by CYP2C8. Similarly, the acyl glucuronide of clopidogrel, a widely used antiplatelet agent, is a potent time-dependent inhibitor of CYP2C8 that demonstrated significant DDI with the substrates of CYP2C8. Current progress in atomic-level understanding mostly involves studying how different drugs bind and undergo oxidation in the active site of CYPs. It is not clear how an acyl glucuronide metabolite of the drug gemfibrozil or clopidogrel interacts in the active site of CYP2C8 and selectively inhibit the enzyme. This mini-review summarizes the current knowledge on some of the important clinical DDI caused by gemfibrozil and clopidogrel due to the inhibition of CYP2C8 by acyl glucuronide metabolites of these drugs. Importantly, it examines recent developments and potential applications of structural biology tools to elucidate the binding and orientation of gemfibrozil acyl glucuronide and clopidogrel acyl glucuronide in the active site near heme that contributes to the inhibition and inactivation of CYP2C8.

Abstract licence: CC BY